Page 146 - 《中国药房》2026年1期

Predictive biomarkers of oxaliplatin-induced peripheral ropathy in south Indian cancer patients[J]. Asian Pac J
neurotoxicity[J]. J Pers Med，2021，11（7）：669. Cancer Prev，2017，18（11）：3157-3165.
[28] LEE K H，CHANG H J，HAN S W，et al. Pharmacoge‐ [38] 孔连广，彭俊玲，郑祥珍，等 . SCN10A rs12632942 单核
netic analysis of adjuvant FOLFOX for Korean patients 苷酸多态性与结直肠癌化疗奥沙利铂外周神经毒性的
with colon cancer[J]. Cancer Chemother Pharmacol， 相 关 性 [J]. 中 国 肿 瘤 生 物 治 疗 杂 志 ，2019，26（7）：
2013，71（4）：843-851. 788-792.
[29] 张诗慧，丁伶清，林美钦，等. 基因多态性与结直肠癌患 [39] NAM Y W，DOWNEY M，RAHMAN M A，et al. Chan‐
者奥沙利铂化疗不良反应的相关性 [J]. 中国新药杂志， nelopathy of small- and intermediate-conductance Ca
2018，27（13）：1572-1576. （2+）-activated K（+） channels[J]. Acta Pharmacol Sin，
[30] KJERSEM J B，THOMSEN M，GUREN T，et al. AGXT 2023，44（2）：259-267.
and ERCC2 polymorphisms are associated with clinical [40] BASSO M，MODONI A，SPADA D，et al. Polymorphism
outcome in metastatic colorectal cancer patients treated of CAG motif of SK3 gene is associated with acute oxali‐
with 5-FU/oxaliplatin[J]. Pharmacogenomics J，2016，16 platin neurotoxicity[J]. Cancer Chemother Pharmacol，
（3）：272-279. 2011，67（5）：1179-1187.
[31] BALLARINI E， MALACRIDA A， RODRIGUEZ- [41] ANON B，LARGEAU B，GIRAULT A，et al. Possible
MENENDEZ V，et al. Sodium-calcium exchanger 2：a association of CAG repeat polymorphism in KCNN3 en‐
pivotal role in oxaliplatin induced peripheral neurotoxicity coding the potassium channel SK3 with oxaliplatin-
and axonal damage? [J]. Int J Mol Sci，2022，23（17）： induced neurotoxicity[J]. Cancer Chemother Pharmacol，
10063. 2018，82（1）：149-157.
[32] FANG H J，HU W J，KANG Q Y，et al. Clinical characte- [42] ARGYRIOU A A， ANTONACOPOULOU A G，
ristics and genetic analysis of pediatric patients with so‐ ALBERTI P，et al. Liability of the voltage-gated potas‐
dium channel gene mutation-related childhood epilepsy：a sium channel KCNN3 repeat polymorphism to acute
review of 94 patients[J]. Front Neurol，2023，14：1310419. oxaliplatin-induced peripheral neurotoxicity[J]. J Peripher
[33] GOODWIN G，MCMAHON S B. The physiological func‐ Nerv Syst，2019，24（4）：298-303.
tion of different voltage-gated sodium channels in pain[J]. [43] GARZIERA M，VIRDONE S，DE MATTIA E，et al. HLA-
Nat Rev Neurosci，2021，22（5）：263-274. G 3′UTR polymorphisms predict drug-induced G3-4
[34] ARGYRIOU A A，CAVALETTI G，ANTONACOPOULOU toxicity related to folinic acid/5-fluorouracil/oxaliplatin
A，et al. Voltage-gated sodium channel polymorphisms （FOLFOX4） chemotherapy in non-metastatic colorectal
play a pivotal role in the development of oxaliplatin- cancer[J]. Int J Mol Sci，2017，18（7）：1366.
induced peripheral neurotoxicity：results from a prospec‐ [44] PALUGULLA S，DEVARAJU P，KAYAL S，et al. Genetic
tive multicenter study[J]. Cancer，2013，119（19）：3570- polymorphisms in cyclin H gene are associated with
3577. oxaliplatin-induced acute peripheral neuropathy in South
[35] SERENO M，GUTIÉRREZ-GUTIÉRREZ G，RUBIO J Indian digestive tract cancer patients[J]. Cancer Che‐
M，et al. Genetic polymorphisms of SCN9A are associated mother Pharmacol，2018，82（3）：421-428.
with oxaliplatin-induced neuropathy[J]. BMC Cancer， [45] CECCHIN E，D’ANDREA M，LONARDI S，et al. A pro‐
2017，17（1）：63. spective validation pharmacogenomic study in the adju‐
[36] 张官平，欧阳喜，潘华，等. 结直肠癌患者SCN9A遗传变 vant setting of colorectal cancer patients treated with the 5-
异与奥沙利铂外周神经毒性易感性研究[J]. 广东医学， fluorouracil/leucovorin/oxaliplatin （FOLFOX4） regimen
2017，38（2）：300-304. [J]. Pharmacogenomics J，2013，13（5）：403-409.
[37] PALUGULLA S，THAKKAR D N，KAYAL S，et al. Asso‐ （收稿日期：2025-07-10 修回日期：2025-12-29）
ciation of voltage-gated sodium channel genetic polymor‐ （编辑：胡晓霖）
phisms with oxaliplatin-induced chronic peripheral neu‐

· 136 · China Pharmacy 2026 Vol. 37 No. 1 中国药房 2026年第37卷第1期